As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug
You may also be interested in...
India's DCGI Halts Avandia's TIDE Trial Aimed At Proving CV Safety; Steps Up Review of "Controversial Drugs" Sold In India
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).